Cargando…
The Effect of Monthly Anti-CD25(+) Treatment with Basiliximab on the Progression of Chronic Renal Dysfunction after Lung Transplantation
BACKGROUND: Chronic renal dysfunction (CRD), as predominantly related to calcineurin-inhibitor (CNI) nephrotoxicity, is associated with increased morbidity and mortality after lung transplantation (LTx). Basiliximab (BSX), a recombinant chimeric monoclonal antibody against CD25(+) on activated T-lym...
Autores principales: | Ross, D. J., Belperio, J., Natori, C., Ardehali, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Avicenna Organ Transplantation Institute
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471613/ https://www.ncbi.nlm.nih.gov/pubmed/32913585 |
Ejemplares similares
-
The role of basiliximab in the evolving renal transplantation immunosuppression protocol
por: Salis, Paola, et al.
Publicado: (2008) -
Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009) -
Efficacy of basiliximab induction in poorly matched living donor renal transplantation
por: Gundlapalli, S., et al.
Publicado: (2013) -
Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
por: Oh, Chang-Kwon, et al.
Publicado: (2012) -
Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates
por: Kim, Ha Eun, et al.
Publicado: (2021)